Introduction
Nitrogen heterocycles are of special interest as they constitute an important class of natural and non-natural products as they occupy a key position in the area of drugs and pharmaceuticals [1] [2] . Pyrroles have drawn considerable attention due to their synthetic importance and useful biological activities that are extensively used in drug discovery [3] . Pyrrole derivatives exhibited a vital role in many pharmacological activities including anti-inflammatory [4] - [13] , anti-microbial [14] - [19] , anti-fungal [20] - [22] , antiviral [23] - [25] and anti-cancer [26] - [28] activities.
It is well known that the anti-inflammatory activity is due to the ability to inhibit the cyclooxygenase (COX) activity of prostaglandin H synthase, an enzyme which mediates the production of prostanoids (including prostaglandins, prostacyclins and thromboxanes) from arachidonic acid. Prostaglandins act as mediators in the process of inflammation, thus the discovery of COX-2 specific inhibitors (Coxibs), which their pharmacological properties are correlated to their ability to decrease the COX-2 dependent prostanoid biosynthesis, providing a rational for the development of drug devoid of GIT disorders while retaining clinical efficacy as anti-inflammatory agent [29] . The recent market withdrawal of some coxibs such as rofecoxibs (Vioxx ® ) and valdecoxib (Bextra ® ) due to their adverse cardiovascular side effects [30] clearly delineates the need to explore and evaluate alternative templates with COX-2 inhibitory activity.
Therefore, our aim was to design derivatives of existing clinically used NSAIDs, such as Tolmetin and Ketorolac [31] [32] which are well known pyrrole derivatives acting as anti-inflammatory drugs. In the light of these facts, this paper deals with the synthesis of novel pyrrole and condensed pyrrole derivatives and evaluates them for their anti-inflammatory activity. Furthermore, the extent of the pharmacological effects of pyrrole derivatives is reported to depend on the active groups which are attached to it, as several scientists have elucidated that in pyrrole system positions 2 and 3, it can be suitably modified by the introduction of groups [28] , aromatic [19] [ 25] or heterocyclic moieties to show excellent pharmacological results [12] .
Results and Discussion

Chemistry
Reaction of 4-chlorophenacyl bromide 1 either with 3-trifluoromethyl aniline 2a in refluxing ethanol or by stirring with 3-amino pyridine 2b in diethyl ether afforded 2-(substituted amino)-1-(4-chlorophenyl)ethanones 3a,b; respectively which upon stirring with the active methylene bearing carbonitriles namely; malononitrile and ethyl cyanoacetate in sodium ethoxide afforded 3-substituted-2-amino-4-(4-chlorophenyl)-1-(substitutedaryl)-1H-pyrroles 4a-d which were utilized as building units for novel substituted pyrrole compounds (Scheme 1). Furthermore, the o-aminonitrile derivatives 4a,b were condensed with the appropriate aromatic aldehyde namely; benzaldehyde and 2,4-dichlorobenzaldehyde in absolute ethanolto afford the corresponding benzylidenimino derivatives 5a-d (Scheme 2). Moreover, reaction of compounds 4a,b either with ethyl cyanoacetate or malononitrile in refluxing ethanol yielded 6-oxopyrrolo [2,3-b] pyridines 6a,b and 4,6-diamino-pyrrolo [2,3-b] pyridine derivatives 7a,b; respectively. Additionally, cyclization of compounds 4a,b with hydroxylamine hydrochloride in boiling sodium ethoxide afforded the aminopyrazole derivatives 8a,b.
Furthermore, compounds 4a,b were reacted with urea/thiourea in sodium ethoxide to give the target compounds 9a-d (Scheme 3), which were cyclized upon refluxing in pyridine to afford the pyrrolopyrimidine derivatives 10a-d which can also be obtained through refluxing of the o-aminonitrile derivatives 4a,b with urea/ thiourea in a mixture of glacial acetic acid and concentrated hydrochloric acid (3:1). Furthermore, the target phenylthioureaderivatives 11a,b was obtained via refluxing of compounds 4a,b with phenyl isothiocyanate in absolute ethanol. Also, refluxing of compounds 11a,b in pyridine afforded the cyclized compounds 4-iminopyrrolopyrimidine-2-thiones 12a,b which were also prepared directly via refluxing of compounds 4a,b with phenyl isothiocyanate in dry pyridine.
Moreover, our goal was directed to synthesize various substituted pyrrole-3-carbonitrile derivatives bearing different substituted imino side chains in position two of pyrrole (Scheme 4). Therefore, refluxing of compounds 4a,b in a mixture of triethyl orthoformate and acetic anhydride furnished compounds 13a,b with a replaceable ethoxymethyleneimino function which were cyclized upon reaction with ammonia in refluxing methanol via elimination of an ethanol moiety to yield 4-aminopyrrolopyrimidine derivatives 14a,b which were also obtained directly through refluxing of compounds 4a,b with formamide. On the other hand, stirring of compounds 13a,b with dimethylamine in absolute ethanol afforded N,N-dimethyl formimidamide derivatives 15a,b which was also synthesized directly via refluxing compounds 4a,b with dimethylformamide/dimethylacetal in xylene. Moreover, acylation of compounds 4a,b was accomplished through refluxing of compounds 4a,b with p-toluene sulphonyl chloride in toluene to afford 4-methylbenzenesulfonamides 16a,b via elimination of a hydrochloride molecule. Also, partial hydrolysis of compounds 4a,b was accomplishedby stirring at room temperature with concentrated sulfuric acid to afford substituted-2-aminopyrrol-3-carboxamides 17a,b (Scheme 5), which undergo cyclization into pyrrolo [2,3- Moreover, chlorination of pyrrolopyrimidin-4-one derivatives 18a,b with excess phosphorus oxychloride followed by alkalinization to pH 10 using sodium bicarbonate furnished 4-chloropyrrolo [2,3-d] pyrimidines 21a,b (Scheme 6). However, the chlorinated compounds 21a,b were reacted with morpholine in ethanol under reflux in presence of a catalytic amount of triethylamine to furnish the 4-morpholino-pyrrolo [2,3- Furthermore, stirring of compounds 13a,b with hydrazine hydrate 98% in absolute ethanol afforded 4-imino-4,7-dihydro-3H-pyrrolo [2,3-d] pyrimidines 24a,b (Scheme 7) which were used as good starting materials for preparation of several pyrrolo [3,2-e] [1, 2, 4] triazolo [1,5-c] pyrimidine derivatives. Thus, compounds 24a,b were reacted with ethyl cyanoacetate in absolute ethanol containing few drops of glacial acetic acid to yield the cyanomethyl triazolopyrimidine derivatives 25a,b. While, refluxing of compounds 24a,b with carbon disulphide in absolute ethanol containing potassium hydroxide yielded the corresponding triazolopyrimidine-2-thione derivatives 26a,b. Moreover, the reaction of the precursors 24a,b with triethyl orthoformate in absolute ethanol gave the unsubstituted triazolopyrimidine compounds 27a,b. While, upon refluxing of 24a,b with phenyl isothiocyanate in absolute ethanol in presence of a catalytic amount of triethylamine afforded the phenyl amine substituted triazolopyrimidine derivatives 28a,b.
Heating of the o-aminonitrile derivatives 4a,b with sodium azide in presence of ammonium chloride in dimethylformamide as a solvent to furnish 2-aminopyrrol-3-tetrazole derivatives 29a,b (Scheme 8). However, heating compounds 4a,b with ethylene diamine in the presence of carbon disulphide afforded the target compounds 2-aminopyrrol-3-imidazole derivatives 30a,b. Also, the o-aminonitrile derivatives 4a,b were refluxed with carbon disulphide in dry pyridine to yield the pyrrolopyrimidine-2,4-dithiones 31a,b. Besides, pyrrolo [2,3-d] [1, 2, 3] triazin-4-ones 32a,b were obtained via stirring of compounds 4a,b with sodium nitrite solution in a mixture of glacial acetic acid and concentrated hydrochloric acid at 0˚C -5˚C. The reaction mechanism is suggested to proceed first through partial hydrolysis of the cyano function to afford the corresponding o-aminocarboxamide derivatives that undergo subsequent diazotization then coupling with amino function of the carboxamide to yield the target 4-oxotriazine derivatives 32a & 32b.
This work was extended to shed more light on the activity and synthetic potential of the amino and carboxylate groups in compounds 4c,d (Scheme 9). Thus, compounds 4c,d reacted with hydrazine hydrate in absolute ethanol to afford the corresponding acid hydrazide derivatives 33a,b. However, acetylation of amino group in compounds 4c,d with acetic anhydride afforded the target acetamido derivatives 34a,b. However, the synthesis of different hydrazone derivatives through the condensation of hydrazine compounds with monosaccharide is well documented in the literature [33] - [35] . Therefore, this information prompted us to explore the effect of glucose hydrazone derivatives 35a,b whichwere synthesized through the condensation of the hydrazide derivatives 33a,b with glucose in absolute ethanol. Additionally, the reaction of o-acetamidocarboxylate derivatives 34a,b were refluxed with excess hydrazine hydrate in ethanol to afford the target substituted pyrrolopyrimidinone derivatives 36a,b. The reaction mechanism is suggested to proceed first through formation of the hydrazone derivatives followed by tautomerism then intramolecular cyclization via elimination of an ethanol molecule. Finally, the title carboxylic acid derivatives 37a,b was obtained via refluxing of the o-aminoester compounds 4c,d with ethanolic sodium hydroxide (Scheme 10). Also, our aim was extended to develop novel ethyl 1-(substitutedaryl)-4-(4-chlorophenyl)-2-(3-phenylthioureido)-1H-pyrrol-3-carboxylates 38a,b which were obtained via refluxing of 2-aminopyrrole derivatives 4c,d with phenylisothiocyanate in absolute ethanol. Furthermore, fused 2-methyloxazine-4-one rings are reported to be prepared from the reaction of different o-aminocarboxylic acid derivatives with excess acetic anhydride. Thus, the target 2-methyloxazine-4-one derivatives 39a,b were synthesized via refluxing of the o-aminocarboxylic acid compounds 37a,b in excess acetic anhydride. Finally, the thiourea derivatives 38a,b were heated with sodium ethoxide under reflux to furnish the target 2-thioxopyrimidin-4-one derivatives 40a,b.
Biology
All the newly synthesized compounds 4a-40b were preliminarily evaluated for their anti-inflammatory and analgesic activities (using rat paw edema method and writhing test; respectively) as well as their gastric ulcerative effect (ulcerogenicity) an in-vitro antibacterial activity against Staphylococcus aureus (ATCC 25923) as a representative of Gram-positive bacteria; Pseudomonas aeruginosa (ATCC 27853) and Escherichia coli (ATCC 8739) as representatives of Gram-negative bacteria. The compounds were also evaluated for their in-vitro antifungal activity against Candida albicans (ATCC 10231) (using the cup diffusion technique).
Anti-Inflammatory and Analgesic Screening
For the tested compounds 4a-40b, the percent of edema inhibition after 1-6 h and the percent inhibition of the writhing movements are presented in Tables 1-6 . It was revealed from the results that, compounds 4d, 5b, 5c, 5d, 6a, 6b, 9c, 9d, 10d, 12a, 12b, 13b, 19a, 19b, 21b, 23a, 23b, 31a, 31b, 38b and 40a exerted highly potent anti-inflammatory effect, comparable to that of indomethacin (Indocin ® ) at 6 h interval post carrageenan showing inhibition potency ranging from 1.01% -1.05%. While, compounds 4b, 4c, 5a, 7a, 7b, 8b, 9a, 9b, 9c, 10b, 10c, 11a, 11b, 13a, 13b, 14b, 15b, 16a, 16b, 18a, 18b, 20b, 21a, 24a, 25b, 26a, 26b, 28b, 32a, 32b, 34a, 34b, 38a and 40b exerted moderate anti-inflammatory activity at 6 h interval post carrageenan, comparable with that of indomethacin (Indocin ® ) showing inhibition potency ranging from 0.68% -1%.
In addition to, compounds 4a, 8a, 10a, 14a, 15a, 22a, 22b, 25a, 27a, 27b, 28a, 29a, 29b, 30a, 30b, 33a, 33b, 35a, 35b, 36a, 36b, 37a, 37b, 39a and 39b which showed weak anti-inflammatory activity at 6 h interval less than indomethacin showing inhibition potency ranging from 0.36% -0.67%. The activity profiles of all the previous compounds were the same as indomethacin (response increasing by time).
It is worth mentioning that, the highly potent compounds were those comprising 3-cyanopyrrole rings attached to different side chains in the 2 position, among these chains are the aryl imino function as in compounds 5b-d, thiourea group as in compounds 9c,d and ethoxymethyleneimino chain in compound 13b. Also, compounds containing pyrrole-3-carboxylate with the 2 position either unsubstituted as in compound 4d or substituted with thiourea side chain as compound 38b were highly potent.
Furthermore, among the highly potent compounds were thefused pyrrolopyrimidine compounds bearing 2-thioxo function with different substituents in the 4 position. Among these groups in the 4 position was the amino group as compound 10d, imino function in compounds 12a,b, 4-thioxo function as in compounds 31a,b and 4-oxo group as in compound 40a. Also, the 4-chloropyrrolopyrimidine derivative 21b as well as the 4-hydrazinopyrrolopyrimidine analogue 23b exhibited potent activity comparable to the reference drug Indomethacin (Indocin   ®   ) . Moreover, other fused pyrrole compounds such as the pyrrolopyridine-2-one derivatives 6a,b and the pyrrolo[1,2,6]thiadiazine-2,4-dione analogues 19a,b exerted excellent activity.
As revealed from the results presented in Tables 1-3 that, compounds 4d, 5c, 5d, 6b, 10c, 10d, 17b, 31a and 31b exhibited the most potent analgesic activity with potency ranging from 1 -1.10 to the reference drug Indomethacin. It is to be noted that some functions are assumed to be responsible for the highly potent analgesic activity of these compounds. Among these functions are the ester function in 3-position as in compound 4d, the 2,4-dichlorobenzylidine imino function in pyrrole-2-position as in compounds 5c and 5d and pyrrolopyridine moiety in compound 6b. Also, the pyrrolopyrimidine thione function as in compounds 10c and 10d.
Furthermore, the carboxamide function as in compound 17b led to high analgesic activity. Additionally, pyrrolopyrimidine dithione function as in compounds 31a and 31b exerted the most potent analgesic activity.
Ulcerogenicity
Five compounds that exhibited the most potent anti-inflammatory activity; 12b, 23b, 31a, 31b and 38b were evaluated for their ulcerative effect on rats as revealed in Table 7 . Table 7 . Ulcerogenic effects of the tested compounds. In general, all the tested compounds showed better results than the reference drug Indomethacin. Especially, compounds 12b and 31b which were devoid of any ulcerative effect compared to 94% of that of Indomethacin as illustrated in the previous table.
Anti-Microbial Screening
For the tested compounds 4a-40b, the resulting inhibition zones were measured in mm diameter, Tables 8-10 .
Among the tested compounds, compounds 5d, 9d, 11b, 12a, 13b, 15a, 15b, 17a, 22a, 27a, 32a, 33a, 39a and 39b were found to be the most active. Among the different functions attached to the free pyrrole ring which exerted potent antimicrobial activity against Gram negative bacteria are the 2,4-dichlorobenzylidineimino, thiourea, phenylurea, ethoxymethyleneimino as well as dimethylaminomethyleneimino groups as in compounds 5d, 9d, 11b, 13b and 15a, 15b; respectively, in addition to, the carboxamide and the acid hydrazide side chains attached to the pyrrole ring in compounds 17a and 33a; respectively.
Furthermore, functions surmounted on the pyrrolopyrimidine skeleton as 4-imino-3-phenyl-2-thione and 4-morpholino groups as in compounds 12a and 22a; respectively, also displayed significant antimicrobial activity. Besides to, the triazolopyrrolopyrimidine derivative 27a, pyrrolotriazine analogue 32a as well as the pyrroloxazine compounds 39a, 39b which exerted high antimicrobial activities against Gram negative bacteria. It is worth mentioning that, all compounds exerted weak activity against Gram positive bacteria except for the 3-imidazolidine substituted pyrrole derivative 30b which exerted moderate antimicrobial activity. However, only the pyrrolopyrimidinone derivative 18a and the 1,2,6-thiadiazine-2,4-dione analogue 19a exerted moderate antifungal activity against C. albicans.
Computer Aided Docking
The most active twenty compounds as anti- inflammatory agents 4d, 5b, 5c, 5d, 6a, 6b, 9c, 9d, 10d, 12a, 12b,  13b, 19a, 19b, 21b, 23b, 31a , 31b, 38b and 40a were subjected to docking using Molecular Operating Environment (MOE) program [36] on the 3D structure of the cyclooxygenase-2 enzyme (COX-2) in a trial to predict their mode of action as anti-inflammatory drugs.
Docking on the Active Site of Cyclooxygenase-2 Enzyme (COX-2) 1) Diclofenac interactions with the active site of COX-2:
Diclofenac interacted as hydrogen bond acceptor via four hydrogen bonds via both the oxygen atoms of car-boxyl group with the amino acid residues Tyr 385 (2.73 A˚) and Ser 530 (2.65 A˚, 2.91 A˚ and 3.04 A˚) as shown in Figure 1 .
Docking of Compound 4d into COX-2
Active site revealed that several molecular interactions were considered to be responsible for the observed affinity, as the N of pyridine moiety acted as a hydrogen bond acceptor with the side chain residue; His 90 (2.25 A˚) with a strength of 81.3%. In addition to a hydrogen bond interaction between the hydrogens of the amino group which acted as a hydrogen bond donor with the side chain residue Tyr 355 (2.61 A˚) with a strength of 5.3%. Besides to, hydrophobic interactions involving the pyridine C 6 
Docking of Compound 5c into COX-2
Active site illustrated the presence of several interactions of the cyano group with different amino acid residues as it acted as a hydrogen bond acceptor with the side chain residues; His 90, 
Docking of Compound 6a into COX-2
Active site revealed the presence of four hydrogen bonds in which the cyano nitrogen acted as a hydrogen bond acceptor for three hydrogen bonds with the amino acid residues His 90, Arg 513 and Figure 9 .
Docking of Compound 10d into COX-2
Active site revealed hydrogen bond interaction between the N atom of pyridine moiety as it acted as a hydrogen bond acceptor with the side chain residues His 90 and Arg 513 (2.74 A˚ and 3.54 A˚; respectively) with a strength of 21.7% and 1.2%; respectively. Besides to, arene cation interaction between the p-chlorophenyl ring and the amino acid residue Arg 120. In addition to, hydrophobic interactions among the p-chloro phenylC 2 
Docking of Compound 19b into COX-2
Active site revealed the presence of hydrogen bond interactions between the oxygen atoms of pyrimidine C 2 and C 4 oxo functions as they acted as hydrogen bond acceptor with the side chain residue Arg 513 (3.27 A˚, 2.3%) and Arg 120 (2.28 A˚, 9.5%); respectively. In addition to, another hydrogen bond between the pyridyl nitrogen atom as it acted as hydrogen bond acceptor with the amino acid residue Arg 513 ( ), pharmaceutical analytical unit, Faculty of Pharmacy, Al-Azhar University.
1 H-NMR spectra were recorded in (DMSO-d 6 ) at 300 MHz on a Varian Gemini NMR spectrometer (δ ppm) using TMS as an internal standard, ResearchService Unit, Faculty of Science, Cairo University. Mass spectra were recorded on GC MS-QP 5050A mass spectrometer at 70 eV andmicroanalytical data were performed on Elementar Vario EI III CHN analyzer at the microanalytical unit, in Regional center for Mycology and Biotechnology, Al-Azhar University. Thin layer chromatography was performed on precoated (0.25 mm) silica gel GF254 plates (E. Merck, Germany). Compounds were detected with UV lamp at λ 254 nm. 
1-(4-Chlorophenyl)-2-(Pyridin-3-Ylamino)Ethanone; 3b
An equimolar mixture of 4-chlorophenacyl bromide (0.38 g, 2 mmol.) and 3-aminopyridine (0.19 g, 2 mmol.) were stirred for 2 h. at room temperature in (20 mL) diethyl ether. The solid product was collected by filtration and recrystallized from the ethanol. 
General Procedure for Synthesis of Compounds 4a-d
General Procedure for Synthesis of Compounds 5a-d
An equimolar mixture of the appropriate 1-(substitutedaryl)-2-amino-4-(4-chlorophenyl)-1H-pyrrole-3-carbonitrile 4a,b (2 mmol.) and the selected aromatic aldehyde namely; benzaldehyde and 2,4-dichlorobenzaldehyde (2 mmol.) was heated under reflux for 16 h in absolute ethanol (30 mL) containing glacial acetic acid (2 -3 drops). The reaction mixture was allowed to cool and the product was filtered off, washed with ethanol and recrystallized from dioxane.
1) 2-(Benzylidenimino)-4-(4-chlorophenyl)-1-(3-trifluoromethylphenyl)-1H-pyrrole-3-carbonitrile; 5a
Faint yellow needle crystals; yield (55%); m. 
General Procedure for Synthesis of Compounds 6a,b
An equimolar mixture of the selected 1-(substitutedaryl)-2-amino-4-(4-chlorophenyl)-1H-pyrrole-3-carbonitrile 4a,b (2 mmol.) and ethyl cyanoacetate (0.23 g, 0.1 mL, 2 mmol.) was heated under reflux in absolute ethanol (30 mL) for 8 h. The reaction mixture was allowed to cool and the product was collected and recrystallized from glacial acetic acid. 
General Procedure for Synthesis of Compounds 9a-d
The appropriate compound 4a,b (2 mmol.) was refluxed with equimolar amount of urea or thiourea (2 mmol.) in absolute ethanol (20 mL) containing sodium ethoxide [prepared by dissolving sodium metal (0.03 g, 2 mmol.) in absolute ethanol (20 mL)] for 10 h. The reaction was allowed to cool and the solid product was filtered and washed with ethanol. 
General Procedure for Synthesis of Compounds 10a-d Method 1:
A mixture of the selected 1-(substitutedaryl)-2-amino-4-(4-chlorophenyl)-1H-pyrrole-3-carbonitrile 4a,b (2 mmol.) was refluxed and urea (0.12 g, 2 mmol.) and/or thiourea (0.15 g, 2 mmol.) was refluxed for 12 h. in a mixture of glacial acetic acid and HCl (20 mL) (3:1). The reaction was allowed to cool, filtered and washed with ethanol to yield the target compounds 10a-d in an average yield of 82%.
Method 2:
The selected urea or thiourea derivative 9a-d (2 mmol.) was refluxed in pyridine (10 mL) for 16 h. The solvent was evaporated under reduced pressure and the solid obtained was collected to yield the target compounds 10a-d in an average yield of 63%. 
General Procedure for Synthesis of Compounds 12a,b Method 1:
A mixture of the appropriate 1-(substitutedaryl)-2-amino-4-(4-chlorophenyl)-1H-pyrrole-3-carbonitrile 4a,b (2 mmol.) and phenyl isothiocyanate (0.27 g, 0.24 mL, 2 mmol.) was refluxed in pyridine (15 mL) for 10 h and the solid product was filtered, washed with ethanol to yield the target compounds 12a,b in an average yield of 53%.
The selected phenyl thiourea derivatives 11a,b was refluxed in pyridine (10 mL) for 18 h. The solvent was evaporated under reduced pressure to yield the target compounds 12a,b in an average yield of 48%. The appropriate 1-(substitutedaryl)-2-amino-4-(4-chlorophenyl)-1H-pyrrole-3-carbonitrile 4a,b (2 mmol.) was refluxed in excess formamide (30 mL) for 10 h. The reaction mixture was concentrated to the minimum and left to cool then triturated with glacial acetic acid to yield the target compounds 14a,b in an average yield of 66%.
The selected ethyl N-1-(substitutedaryl)-4-(4-chlorophenyl)-3-cyano-1H-pyrrol-2-ylformimidate 13a,b (2 mmol.) was stirred in (100 mL) of methanolic ammonia solution [methanol: ammonia (2:1)] at room temperature for 7 h. The separated solid was then collected to yield the target compounds 14a,b in an average yield of 41%. 
General Procedure for Synthesis of Compounds 17a,b
The selected compound 4a,b (2 mmol.) was stirred at room temperature for 3 h. inconc. sulfuric acid (15 mL) then poured drop by drop on to crushed ice. The reaction mixture was neutralized with ammonium hydroxide and the obtained product was filtered, washed thoroughly with water, left to dry and recrystallized from ethanol. The selected 1-(substitutedaryl)-2-amino-4-(4-chlorophenyl)-1H-pyrrole-3-carbonitrile 4a,b (2 mmol.) was refluxed for 9 h. in excess formic acid 80% (30 mL). The reaction mixture was then concentrated and the obtained product was filtered, washed with ethanol to yield the target compounds 18a,b in an average yield of 52%.
The selected 1-(substitutedaryl)-2-amino-4-(4-chlorophenyl)-1H-pyrrole-3-carboxamide 17a,b (2 mmol.) was refluxed in excess formamide (30 mL) for 8 h. The reaction mixture was concentrated to yield the target compounds 18a,b in an average yield of 67%. 
General Procedure for Synthesis of Compounds 23a,b
A mixture of compounds 21a,b (2 mmol.) and hydrazine hydrate 98% (0.1 g, 0.1 mL, 2 mmol.) was refluxed in absolute ethanol (30 mL) in presence of TEA as a catalyst for 10 h. The reaction mixture was allowed to cool and poured on to crushed ice. The obtained solid was filtered, washed with water and recrystallized from dioxane to yield the target compounds 23a,b; respectively. The screening for anti-inflammatory activity for all the newly synthesized compounds 4a-40b was carried out by using adult albino rats of both sexes weighing 120 -150 g which were obtained from animal house laboratory of Nile company, Cairo, Egypt. Rats were divided into eighty four groups; each group consists of five rats per cage in the Department of Pharmacology, Faculty of Medicine, Al-Azhar University.
The rats were kept under constant temperature 30˚C and 12 hours light/dark cycle. All animals were acclimatized in the animal facility for at least two weeks prior the experiments.
The animals were kept fastened for 24 hours prior to the experiment, but they were allowed free access to water [37] . The animal experiments described below comply with the ethical principles and guidelines for the care and use of laboratory animals adopted by the National Egyptian Community.
The equipment used was Dial micrometer model (120 -1206 Baty, Sussex, England).
2) Anti-inflammatory activity: Rat paw edema assay was carried out according to Winter et al. [38] . Prepared compounds (equimolar to the referencedrug) were dissolved in DMSO and administrated subcutaneously.
One hour after drug administration acute inflammation was induced by injection of 0.05 mL of 1% of carrageenan sodium (Sigma-Aldrich, St. Louis, USA) subcutaneously into the sub planter region of the right hind paw.
The thickness of the injected paw was measured (from dorsal to ventral surfaces) immediately after carrageenan injection and after (1, 2, 3, 4, 5 and 6 hours) by using a micrometer. The size of edema was expressed as the increase in the thickness in mm after carrageenan injection.
The percentage inhibition of edema thickness at each time interval was calculated from the mean effect in control and treated animals according to the equation [39] [40] . where, Tc and Tt are the mean increase in thickness of the carrageenan injected paw of the control group and drug treated groups; respectively. Control group: received the excipients (water mixed with few drops of tween 80) followed by carrageenan after 1 hour. Indomethacin (Indocin ® ) (5 mg/kg) was used as the referencedrug [41] . Then the potencies of compounds were calculated after 6 hours of carrageenan injection where the % edema inhibition reached maximum.
3) Statistical analysis Results are expressed as (mean ± standard deviation) statistically analyzed using two way analysis of variance (ANOVA) followed by Bonferroni test [42] .
Ulcerogenicity
All animals subjected to this experimental test were sacrificed immediately after the last measurement (6 hour), by diethyl ether and stomachs were separated. An opening at the great curvature was made and the stomachs were washed with distilled water and cleaned gently by dipping in normal saline. The mucosal damage was inspected with a 3× magnifying lens for any evidence of hyperemia, hemorrhage or ulcer. For each stomach the mucosal damage was assessed [43] .
The percentage ulceration for each group was calculated as follows:
Number of animals bearing ulcerin a group % Ulceration 100 Total number of animals in the same group = ×
Analgesic Screening 1) Animals:
The screening for analgesic activity for all synthesized compounds 4a-40b was carried out by using mices of both sexes weighing 25 -30 g which were obtained from animal house laboratory, Nile company, Cairo, Egypt.
Mices were divided into eighty four groups; each group consists of four mices per cage in the animal facility of Faculty of Medicine, Al-Azhar University. The mices were kept under constant temperature 25˚C and 12 hours light/dark cycle. All animals were acclimatized in the animal facility for at least two weeks prior the experiments.The animals were kept fastened for 24 hours prior to the experiment, but they were allowed free access to water.
2) Assessment of analgesic screening:
The analgesic activity was evaluated according to writhing test reported by Koster et al. [44] . The newly synthesized compounds (equimolar to the reference drug) were dissolved in DMSO and administrated to the groups orally (using intragastric tube) followed by injection of 0.6% acetic acid solution (10 mL/kg) after 1 hour [45] . Indomethacin (Indocin ® ) (2.5 mg/kg) was used as the reference drug. Stretching movements (arching of the back, developments of the tension in the abdominal muscles, elongation of the body and extension of the forelimbs) were counted as a writhing response. The number of writhes was counted for 15 minutes immediately after the acetic acid injection. The percentage of inhibition of writhes number was calculated as follows: Nc Nt % of Inhibition 100 Nc − = ×
